Remove

PTC/SB/08.c (08-03.)
Approved for use through 97/31/2006. ONS 0851-0231
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number.

	Application Number				
	Filing Date				
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Shinj		ji FURUSHO		
(Not for submission under 37 CFR 1.99)	Art Unit				
(Not for Submission and or or it floor	Examiner Name				
	Attorney Docket Numb	er	YOSHID0024		

II S PATENTS

	U.				U.S.	PATENTS			Remove		
		Kind Code ¹			Name of Pate of cited Docu	entee or Applicant iment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1										
If you wisl	h to a	l dd additional U.S. Pate	nt citatio	n inform	ation pl	l lease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	ublication Number Kind Code1 Publication Name of Patentee or A of cited Document			Relev	s,Columns,Lines where ant Passages or Releves Appear	e vant			
	1										
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d buttor			
				FOREIG	SN PAT	ENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Applicant of cited		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	74	
	1	2001-092796	JP			2001-04-06	Turbo Data Labora	atory		Ø	
	2	2001-147800	JP			2001-05-29	Turbo Data Labora	atory		Z	
	3	2000/010103	wo			2000-02-24	Shinji Furusho			V	

Application Number | Filing Date | First Named Inventor | Share FURUSHO | Art Unit | Examiner Name | Application Number | First Named Inventor | Share FURUSHO | Art Unit | Examiner Name | Attorney Cocket Number | YOSHIDO224

If you wis	h to a	dd add	fitional Foreign Patent Document citation information please	e click the Add butto	n Add	
			NON-PATENT LITERATURE DOCUM	MENTS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the I (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, ctly and/or country where published.					
	1		national Search Report issued in corresponding application No. Pr and mailed December 7, 2004.	CT/JP2004/015439 co	mpleted November 22,	Z
If you wis	h to a	dd add	litional non-patent literature document citation information p	lease click the Add	button Add	
			EXAMINER SIGNATURE			
Examiner	Signa	ture		Date Considered		

See Not Code of USPD Pleat Documents at leave USPD CODY or MEDF 90104. 2 feter of this that issued the document, by the localistic rode (NPD) Standard 873.) 3 feet planese peter foot comment, be indicated or the year of the reper or the precise the senial number of the peter document. See a feet and perfect on the document of the reper of the peter foot peter and peter document. If you consider the peter document of the peter of t

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Diagra con	37	CER .	1 97	and	1 05	t to	make	the	appropriate	coloction/	e)·

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inequiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(c)(d).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

om or the agricult.										
Signature	/Joerg-Uwe Szipl/	Date (YYYY-MM-DD)	2006-04-27							
Name/Print	Joerg-Uwe Szipi	Registration Number	31799							

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.32.11.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.32.213.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.